
American Society of Hematology

64th ASH Annual Meeting and Exposition

Ernest N. Morial Convention Center New Orleans, LA

December 10-13, 2022





Saturday, December 10

653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Bispecific Monoclonal Antibodies in Myeloma

12:00PM - 1:30PM CST

R02-R05

Elranatamab

Presentation 158
Presentation Time: 12:15 PM

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Raje N



Elranatamab

Presentation 159

Presentation Time: 12:30 PM

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort A of the Magnetismm-3 Study

Bahlis NJ



632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I

5:30PM - 7:30PM CST

Hall D

Bosutinib

Presentation 1703

Efficacy and Safety of Bosutinib vs Imatinib by Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia

Deininger MW



Sunday, December 11

653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster I

5:30PM - 7:30PM CST

Hall D

Elranatamab

Presentation 1921

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

Grosicki S



906. Outcomes Research— Myeloid Malignancies: Poster I

5:30PM - 7:30PM CST

Hall D

Glasdegib

Presentation 2320

Real-World Observational Study of Outcomes for Acute Myeloid Leukemia (AML) in Patients Treated with Glasdegib or Venetoclax in US Community Oncology Practices

Gajra A



612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II

6:00PM - 8:00PM CST

Hall D

Inotuzumab ozogamicin

Presentation 2684

Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study

de Lima M



632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II

6:00PM - 8:00PM CST

Hall D

Bosutinib

Presentation 3026

Efficacy and Safety of Bosutinib Versus Imatinib in US Patients with Newly Diagnosed Chronic Myeloid Leukemia after 5-Years Follow-up in the BFORE Trial

Kota VK



Monday, December 12

652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II

6:00PM - 8:00PM CST

Hall D

Elranatamab

Presentation 3192

Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma

Elmeliegy M



905. Outcomes Research— Lymphoid Malignancies: Poster II

6:00PM - 8:00PM CST

Hall D

Inotuzumab ozogamicin

Presentation 3608

Health Care Resource Utilization and Costs Among Patients with Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin and Blinatumomab during First Salvage in Relapse/Refractory

Russell-Smith TA



652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III

6:00PM - 8:00PM CST

Hall D

Elranatamab

Presentation 4509

A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma

Elmeliegy M



653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster III

6:00PM - 8:00PM CST

Hall D


Elranatamab

Presentation 4567

Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma

Landgren CO







The compilation of presentations is for educational purposes only. All materials here are presented for purposes of scientific exchange. They are NOT presented for any promotional purpose. All copyrights protected by law. Solely for non-commercial use.

© Pfizer Inc. All rights reserved.